L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
NAMUR, Région wallonne, Belgium
Send a message
♦ ERC has a unique patented cell-based immunotherapy approach which treats tumours by directly stimulating the patient’s immune system, using whole cells and lysates of autologous (from the patient him/herself) and allogeneic tumour cells (from other patients).
♦ This therapeutic technology has been patented at the international level under the reference PCT/EP2007/050807 (WO/2007/085648).
♦ The vaccine has shown breakthrough performance on compassionate patients suffering from aggressive brain tumours (Glioblastoma Multiforme - GBM). Several patients have shown a regression of the tumour and some, a total disappearance.
♦ Our product outperforms any known standard medical treatment.
ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same, patented technology targeting other types of tumours. The New site is situated in a biotech-focussed area of Kerkenbos in the University city of Nijmegen.
ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination with Gliovac/ERC1671 vs standard treatments without Gliovac/ERC1671 in the treatment of Glioblastoma multiforme. For further information go to the publications page.
Start in 02/2008
Creation of ERC
The company obtained Advanced Medical Therapy Product status for Gliovac/ERC1671 from the EMA.
The company obtained Orphan Drug status for Gliovac/ERC1671 from the US FDA and the status SME (EMA)
First patient reaching total remission.
Phase II FDA Approval in recurrent patients - recruiting. Orphan Drug Status granted by EMA.
to be continued ...